Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
The Methodist Hospital Research Institute
Dana-Farber Cancer Institute
Essen Biotech
University of Nebraska
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Institut Claudius Regaud
Institut Bergonié
University of Alabama at Birmingham
Cancer Research UK
Arbeitsgemeinschaft medikamentoese Tumortherapie
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Universidade Federal de Pernambuco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cedars-Sinai Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
Imperial College London
Roswell Park Cancer Institute
Weprom
University of Dundee
Weill Medical College of Cornell University
Hospices Civils de Lyon
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
CureOne
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Fox Chase Cancer Center
AHS Cancer Control Alberta
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Indiana University
University of Chicago
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Duke University
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center